Aclaris Therapeutics Inc (ACRS)
0.993
-0.01
(-0.70%)
USD |
NASDAQ |
Dec 08, 13:48
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 70.34M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -93.41% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.186 |
| Price to Book Value | 0.4499 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.82% |
Profile
| Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. |
| URL | https://www.aclaristx.com |
| Investor Relations URL | https://www.aclaristx.com/#!investors/juser |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 23, 2024 (est.) |
| Last Earnings Release | Nov. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. |
| URL | https://www.aclaristx.com |
| Investor Relations URL | https://www.aclaristx.com/#!investors/juser |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 23, 2024 (est.) |
| Last Earnings Release | Nov. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |